Hansoh BioMedical R&D Company $3692.HK
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS16
PHASE 3 / 2-37
RECRUITING9
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO0%
Delay Index: of 5 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Hansoh BioMedical R&D Company on the live radar map → 📅 $3692.HK readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| HS-20093 NCT06007729 |
P2 | Recruiting | Head and Neck Squamous Cell Carcinoma | 170 | 2025-12-12 |
| HS-20093 NCT05830123 |
P2 | Recruiting | Osteosarcoma; Sarcoma | 170 | 2025-12-31 |
| HS-20089 NCT06014190 |
P2 | Recruiting | Ovarian Cancer; Fallopian Tube Cancer | 460 | 2025-12-31 |
| HS-20105 NCT06144723 |
P1/2 | Not yet recruiting | Advanced Solid Tumor | 402 | 2026-03 |
| HS-20117 NCT06417008 |
P2/3 | Recruiting | Non-Squamous Non-Small Cell Lung Cancer | 1080 | 2026-06-01 |
| HS-10374 6mg tablets NCT06926582 |
P2 | Not yet recruiting | Psoriasis | 305 | 2026-07-09 |
| HS-20093 NCT06112704 |
P2 | Recruiting | Advanced Solid Tumor | 220 | 2026-07-31 |
| HS-20137 NCT07879885 |
P2 | Recruiting | Moderate-to-severe Plaque Psoriasis | 390 | 2027-03-01 |
| HS-20089 NCT06855069 |
P3 | Recruiting | Ovarian Cancer | 468 | 2027-03-07 |
| HS-20137 NCT06844799 |
P3 | Not yet recruiting | Moderate-to-severe Plaque Psoriasis | 720 | 2027-03-31 |
| HS-20093 NCT06526624 |
P3 | Not yet recruiting | Limited-stage Small-cell Lung Cancer | 406 | 2027-11-30 |
| HS-20093 for Injection NCT07824882 |
P2 | Recruiting | Non-Small Cell Lung Cancer | 76 | 2028-03-30 |
| HS-20093 NCT07464327 |
P3 | Not yet recruiting | Non-Small Cell Lung Cancer | 450 | 2028-12-31 |
| HS-20089 PSOC NCT07821606 |
P3 | Not yet recruiting | Platinum-sensitive Recurrent Ovarian Cancer | 460 | 2029-12-30 |
| Cohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin NCT07283367 |
P1/2 | Recruiting | CRC | 502 | 2029-12-31 |
| HS-20093 for Injection NCT07621601 |
P3 | Not yet recruiting | Esophageal Squamous Cell Carcinoma (ESCC) | 494 | 2030-12-31 |